{"title": "PDF", "author": "PDF", "url": "https://scielo.isciii.es/pdf/fh/v41n5/2171-8695-fh-41-05-00589.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "589Farmacia Hospitalaria 2017\nl Vol. 41 l N\u00ba 5 l 589 - 600 l\nFarmacia\nHOSPITALARIA\n \u00d3rgano oficial de expresi\u00f3n cient\u00edfica de la Sociedad Espa\u00f1ola de Farmacia HospitalariaRegina Juanbeltz et al.\nLos art\u00edculos publicados en esta revista se distribuyen con la licencia\nArticles published in this journal are licensed with a\nCreative Commons Attribution 4.0\nhttps://creativecommons.org/licenses/by-nc-nd/4.0/\nLa  revista Farmacia no cobra tasas por el env\u00edo de trabajos,  \nni tampoco por la publicaci\u00f3n de sus art\u00edculos.\nAbstract\nObjective:  Complementary and alternative medicine (CAM) use has \ngrown considerably, although there is little research on the topic in Spain. \nThe aim of this study was to determine the prevalence of complementary \nmedicine use in adult cancer patients at the same time as they were recei -\nving conventional treatment in a Spanish referral cancer centre.\nMethod:  An observational, descriptive, cross-sectional study was con -\nducted in the Ambulatory Treatment Unit during 2 consecutive weeks in \nMarch 2015. Adult patients who were receiving intravenous chemothera -\npy were included. Study variables were obtained from a questionnaire \nand medical records. \nResults:  316 patients were included. 32.3% of the patients reported \ncomplementary medicine use during this period and 89% were ingesting \nproducts by mouth, herbs and natural products being the most commonly \nused. 81% of patients started to use complementary medicine after diag -\nnosis, and family/friends were the main source of information. 65% of the \npatients reported improvements, especially in their physical and psycholo -\ngical well-being. Significant predictors of CAM use were female gender \n(P=0.028), younger age (P<0.001), and secondary education (P=0.009).\nConclusions:  A large proportion of cancer patients receiving intrave -\nnous chemotherapy also use complementary medicine, which they mainly \ntake by mouth. Due to the risk of chemotherapy-CAM interactions, it is \nimportant for health-professionals to keep abreast of research on this issue, \nin order to provide advice on its potential benefits and risks.Resumen\nObjetivo:  La popularidad de la medicina alternativa y complementaria \nentre los pacientes oncol\u00f3gicos ha incrementado, pero a\u00fan se dispone de \npoca informaci\u00f3n acerca de su empleo en Espa\u00f1a. El objetivo principal \nde este estudio fue determinar la prevalencia del uso de medicina com -\nplementaria en pacientes oncol\u00f3gicos adultos que reciben tratamiento en \nun centro auton\u00f3mico espa\u00f1ol de referencia.\nM\u00e9todo:  Estudio observacional, descriptivo y transversal llevado a cabo \nen un Hospital de D\u00eda de oncolog\u00eda durante 2 semanas de marzo de \n2015. Se incluyeron pacientes adultos que recib\u00edan tratamiento con qui -\nmioterapia intravenosa. Las variables del estudio se obtuvieron a trav\u00e9s \nde un cuestionario y de la historia cl\u00ednica.\nResultados:  Fueron incluidos 316 pacientes; el 32,3% estaba usando \nalg\u00fan tipo de medicina complementaria en ese momento, y el 89% de \nellos lo hac\u00eda a base de una ingesta oral de sustancias, principalmente \nhierbas y productos naturales. El 81% de los pacientes inici\u00f3 la medici -\nna complementaria tras el diagn\u00f3stico, siendo la fuente de informaci\u00f3n \nprincipal familiares/amigos. El 65% refiri\u00f3 sentir mejor\u00eda, principalmente \nbienestar f\u00edsico y ps\u00edquico. Los predictores significativos de uso de MAC \nfueron: ser mujer (p=0,028), edad joven (p<0,001) y un nivel educativo \nmedio (p=0,009). \nConclusiones:  Una proporci\u00f3n importante de los pacientes oncol\u00f3gi -\ncos que reciben quimioterapia intravenosa usan simult\u00e1neamente medi -\ncina complementaria, y esta consiste principalmente en una ingesta oral \nde preparados. Debido al riesgo de interacci\u00f3n con el tratamiento, es \nimportante la formaci\u00f3n de los profesionales sanitarios en este \u00e1mbito, \ncon el fin de poder aconsejar a los pacientes acerca de sus potenciales \nbeneficios y riesgos.\nKEYWORDS\nComplementary therapies; Neoplasms; Antineoplastic agents; \nMedicinal plants; Homeopathy; Prevalence; Spain.\nPALABRAS CLAVE\nMedicina complementaria; C\u00e1ncer; Quimioterapia; Plantas \nmedicinales; Homeopat\u00eda; Prevalencia; Espa\u00f1a.ORIGINALES\nArt\u00edculo biling\u00fce ingl\u00e9s/espa\u00f1ol\nComplementary medicine use in cancer patients \nreceiving intravenous antineoplastic treatment\nUso de medicina complementaria en pacientes \noncol\u00f3gicos sometidos a tratamiento quimioter\u00e1pico \nintravenoso\nRegina Juanbeltz1,2,3, Mar\u00eda Dolores P\u00e9rez-Fern\u00e1ndez1, Bianka Tirapu4,  \nRuth Vera3,5, Susana de la Cruz5, Mar\u00eda Teresa Sarobe1,3\n1Servicio de Farmacia Hospitalaria, Complejo Hospitalario de Navarra. 2CIBER Epidemiolog\u00eda y Salud P\u00fablica. 3Instituto de Investigaci\u00f3n Sanitaria de Navarra-\nIdiSNA. 4Servicio de Farmacia Hospitalaria, Hospital Garc\u00eda Orcoyen. 5Servicio de Oncolog\u00eda M\u00e9dica, Complejo Hospitalario de Navarra. Spain.Autor para correspondencia\nCorreo electr\u00f3nico: \nregina.juanbeltz.zurbano@navarra.es\n(Regina Juanbeltz) \nRecibido el 11 de abril de 2017; \naceptado el 8 de mayo de 2017 .\nDOI: 10.7399/fh.10805\n004_10805- Uso de medicina complementaria en pacientes oncologicos.indd   589 24/08/2017   20:16590Farmacia Hospitalaria 2017\nl Vol. 41 l N\u00ba 5 l 589 - 600 l\nRegina Juanbeltz et al.\nIntroduction\nThe use of CAM among cancer patients is high and is also higher than \nits use in the general population1-2. Most of the information on this topic has \nbeen provided by studies conducted in the United States, which show that \nup to 90% of these patients use complementary medicine3-5. However, there \nare few European studies on this topic. In 2005, a European study was \nconducted across 14 countries. It was found that the overall prevalence of \nCAM use among cancer patients was 35.9%. Spain had the fourth lowest \nconsumption (29.8%)6.\nCAM users are more likely to be younger, women, and married and \nto have a high educational level and annual income6-7. CAM use is more \ncommon in patients with breast, lung, and gastrointestinal cancer8,9. Dietary \nsupplements, herbal remedies, homeopathic remedies, vitamins, and minerals \nare some of the most popular types of CAM used by these patients10 -11. These \ntypes of products are taken by mouth and therefore could affect the thera -\npeutic safety of patients, as suggested by studies that have found interactions \nbetween a range of substances, mainly herbs, and chemotherapy12-13.\nIn Spain, the prevalence of CAM use is unknown in patients diagnosed \nwith cancer and, in particular, in those who continue treatment. This aspect \nis of particular interest because of the potential risk of interaction.\nThe main objective of this study was to determine the proportion of can -\ncer patients who use complementary medicine while receiving intravenous \nchemotherapy prescribed according to usual clinical practice.\nSecondary objectives were: to investigate the type and duration of \nCAM use, the sources of information used, the effect of CAM as perceived \nby patients, and to characterise the socio-demographic and clinical profile \nof CAM users.Methods\nDesign and patients\nAn observational, descriptive, cross-sectional study was conducted in \nthe ambulatory treatment unit of the reference hospital of the Autonomous \nCommunity of Navarre, Spain.\nPatients referred for treatment during 2 consecutive weeks in March \n2015 were invited to participate in the study. Inclusion criteria were: being \nat least 18 years, having a confirmed diagnosis of cancer, and receiving \nintravenous chemotherapy. The exclusion criterion was: language difficulties \nin the oral and written comprehension of the questionnaire.\nThe participants gave informed written consent in which they authorized \naccess to their clinical history. They were also given an information sheet \nwith a contact telephone number.\nThe variables studied were obtained through electronic medical re -\ncords and a interviewer-guided questionnaire, which was completed in \nthe treatment rooms. The study was conducted in accordance with the \nDeclaration of Helsinki and current Spanish legislation (ministerial order \nSAS/3470/2009 for observational studies). The protocol was assessed \nby the Clinical Research Ethics Committee of the Autonomous Community \nof Navarre and classified by the Spanish Medicines and Health Products \nAgency as a \u201cPostauthorization Study with a design other than prospective \nfollow-up\u201d (Spanish acronym: EPA-OD).\nQuestionnaire  \nIn the absence of a validated questionnaire, one was designed following \na review of the literature and subsequently assessed by an oncologist, two \nFigure 1.  Questionnaire on complementary and alternative medicine use.QUESTIONNAIRE ON COMPLEMENTARY AND ALTERNATIVE  \nMEDICINE USE\nAll responses are voluntary and confidential.\nMark appropriate boxes with an \u201cX\u201d.\nDate of birth:  ................................  Place of residence:  ............................\nGender:\nMarital status:\nEducational level:\nARE YOU CURRENTLY using some complementary or alternative medicine apart \nfrom treatment from the ambulatory treatment unit? \nPlease indicate which (you can mark more than one)Man Woman\n  \nSingle Married Partnered Divorced Widow/widower\n  \nNo effect Improvement Adverse effects\n  Noneducated Primary Secondary BaccalaureateIntermediate/advanced \nvocational trainingUniversity\n  \n None\n Products taken by mouth:\n Homeopathic remedies \n Medicinal herbs\n Vitamin and/or mineral complexes\n  \u201cNatural\u201d remedies: scorpion venom, shark cartilage, mistletoe, \nmedicinal fungi, etc.\nNAME OF THE PRODUCT USED (if you can remember):\n .....................................................................................................\n Other: yoga, osteopathy, acupuncture, electromagnetic fields, aromatherapy\n ................................................................................................................Please indicate when you began the use of alternative medicine:\n BEFORE the cancer diagnosis\n AFTER the cancer diagnosis\nAPPROXIMATE START DATE of complementary or alternative medicine:\n .........................................................................................................\nPlease indicate the source of information on complementary medicine:\nTV  Magazines   Radio   Internet  \nFamily/friends   Physician   Pharmacist  \nOther:  .......................................................................................................\nWhat was the effect of using complementary or alternative medicine?\nIf there was an improvement, please describe how it helped you:\n...................................................................................................................\n...................................................................................................................\n...................................................................................................................\nIf there was an adverse effect, please describe what it was:\n...................................................................................................................\n...................................................................................................................\n...................................................................................................................\n  I authorize the researcher to contact me by telephone if needed to obtain \nfurther information on my use of alternative medicine.\nTelephone: ........................................................................................\nThank you very much for your collaboration.\n004_10805- Uso de medicina complementaria en pacientes oncologicos.indd   590 24/08/2017   20:16591Farmacia Hospitalaria 2017\nl Vol. 41 l N\u00ba 5 l 589 - 600 l\nComplementary medicine use in cancer patients receiving intravenous antineoplastic treatment\nepidemiologists, and a clinical pharmacist (Figure 1). The questionnaire \ncomprised 9 questions that collected the following information:\n\u2022 Socio-demographic data: gender, age, place of residence, marital sta -\ntus, and educational level.\n\u2022 Current CAM use: type of CAM used, beginning of CAM use (before \nor after cancer diagnosis), duration of CAM use, sources of information, \nand perceived results (no result, improvement, or adverse effects).\nBased on whether the complementary medicine was taken by mouth or \notherwise, the types of CAM were classified into two large groups: \u201cOral intake \nof some product\u201d or \u201cOther\u201d. If the patient marked the box \u201cOral intake\u201d, they \nwere asked to identify the products as homeopathic remedies, herbs, vitamins \nand/or minerals, or natural remedies. Changes in diet and food were not con -\nsidered as CAM, except for food marketed in the form of capsules and tablets, \namong others, and products from traditional Chinese medicine taken by the pa -\ntient with therapeutic intent. If the patient marked the box \u201cOther\u201d, they were asked \nto identify the approach (e.g., yoga, osteopathy, acupuncture, electromagnetic \nfields, etc). Both sections contained a free field for further comments. The last item \nrequested a telephone number. If authorized by the participant, the researcher \ncould call the patient to obtain more information on the type of CAM used.\nSubsequently, the clinical data of the patients were collected using the \nelectronic medical history system of the Navarre Health Service:\n\u2022 Cancer diagnosis (type of tumour, stage, and time of diagnosis).\n\u2022 Number of cancer treatment lines received.\n\u2022 Surgery and/or radiotherapy as treatment.\nStatistical analysis\nAll statistical analyses were conducted using the IBM SPSS V22.0 soft -\nware package for Windows. A descriptive study was conducted using \nfrequency and proportion analysis for qualitative variables (expressed as \nnumber and percentage), and position measurements for the quantitative \nvariables age and duration of CAM use.\nSimple logistic regression analysis was used to determine the potential \npredictors of CAM. We estimated the raw odds ratios (OR) and their 95% \nconfidence intervals (95%CI).\nResults\nParticipants\nDuring the 2-week sampling period, 539 people attended the ambula -\ntory cancer treatment unit for intravenous treatment. Of these patients, 58 \n(10.8%) did not receive treatment and therefore did not access the rooms in \nwhich the study was being conducted. A further 108 patients could not be \ncontacted. At this point the initial sample comprised 373 patients.\nHowever, 53 patients decided not to take part and 4 patients were \nexcluded: 3 were excluded due to their inability to understand the question -\nnaire because of their lack of knowledge of the Spanish language, and 1 \npatient was excluded due to a psychiatric diagnosis.\nThus, the final sample comprised 316 patients (84.7% of the initial sample). \nTwelve patients (3.8%) were contacted by telephone to obtain further information.\nSociodemographic and clinical characteristics\nThe sociodemographic and clinical characteristics of the patients are \nshown in Table 1.\nA total of 173 women (54.7%) participated in the study, and the mean \nage of the patients was 61 years (range, 24-85 years). Almost half of the \nparticipants lived in rural areas and almost three-quarters of the participants \nwere married. In total, 16% had a university degree.\nThe most common diagnosis was breast cancer (32.3%), followed by co -\nlorectal and lung cancer. The median time elapsed since diagnosis was 12 \nmonths (range, 0-266 months). A total of 222 patients (70%) had undergone \nsurgical intervention and 138 (44%) had received radiotherapy. Ten (3.2%) pa -\ntients were participating in clinical trials at the time of their inclusion in the study.\nCAM Use\nThe simultaneous use of CAM and conventional treatment with che -\nmotherapy was reported by 102 patients (32.3%).In total, 89% of the participants who used CAM took preparations by \nmouth. The most commonly ingested products were herbs (n = 60, 66%), \nfollowed by natural remedies (n = 35, 38.5%), vitamins/minerals (n = 32, \n35.2%), and homeopathic remedies (n = 16, 17 .6%).\nA total of 51 different herbs were being used. The most commonly used \nherbs were turmeric (1 1.7%) followed by cat\u2019s claw (8.3%), liquorice (8.3%), \nthyme (8.3%), thistle (6.7%), melissa (6.7%), and echinacea (5%). A total \nof 33 different natural remedies were in use. Of these, the most common \nwere medicinal fungi used in traditional Chinese medicine (14.3%), lactoba -\ncillus (14.3%), royal jelly (1 1.4%), propolis (1 1.4%), algae such as spirulina \nand blue-green algae (8.6%), saccharomyces (8.6%), radish (5.7%), black \ngarlic (5.7%), and ginger (5.7%). The most common vitamin supplements \nused were vitamin C (50%), followed by B vitamins (31.3%), and vitamin E Table 1.  Sociodemographic and clinical characteristics of the patients\nVariable n %\nGender\n Woman 173 54.7\nPlace of residence\n Urban\n Rural166\n15052.5\n47.5\nMarital status\n Single\n Married\n Partnered\n Divorced\n Widow/widower\n Unknown47\n228\n9\n10\n21\n114.9\n72.2\n2.8\n3.2\n6.6\n0.3\nAge\n \u2264 55 y\n > 55 y94\n22229.7\n70.3\nEducational level\n No education or primary\n Secondary*\n Higher\u2020144\n122\n5045.6\n38.6\n15.8\nType of cancer\n Breast\n Colorectal\n Lung\n Gynaecological\n Head-neck\n Gastric\n Pancreatic\n Other\u2021\n Unknown102\n80\n44\n20\n15\n11\n10\n32\n232.3\n25.3\n13.9\n6.3\n4.7\n3.5\n3.2\n10.2\n0.6\nCancer grade\u00a7\n I\n II\n III\n IV\n Unknown34\n42\n37\n202\n110.8\n13.3\n11.7\n63.9\n0.3\nNo. treatment lines\u01c1\n 1\n 2-3\n \u2265 4\n Unknown152\n115\n48\n148.1\n36.4\n15.2\n0.3\nTotal 316 100\n* Includes secondary education, intermediate or advanced vocational training, and \nbaccalaureate.\n\u2020 University education.\n\u2021 Tumours with a prevalence of less than 10 patients in the study sample.\n\u00a7 Cancer grade at the time of the study, based on the TNM classification of the \u201cAme -\nrican Joint Committee on Cancer\u201d (AJCC). Available at: https://cancerstaging.org/\n\u01c1Chemotherapy, immuno-oncological therapy, and hormonal therapy.\n004_10805- Uso de medicina complementaria en pacientes oncologicos.indd   591 24/08/2017   20:16592Farmacia Hospitalaria 2017\nl Vol. 41 l N\u00ba 5 l 589 - 600 l\nRegina Juanbeltz et al.\n(18.8%). The most common mineral salts used were zinc (21.9%), followed \nby magnesium (15.6%), bicarbonate (9.5%), and copper (9.4%). The most \ncommon homeopathic products used were Miracle Mineral Supplement \n(MMS; composition sodium chlorite, hemlock, and carcinosinum), which \nwas taken by 43.8% of the participants who used homeopathy, and \nSchussler\u2019s Salts (31.3%).\nOf the total number of CAM users, 37 (36.3%) practiced \u201cmind-body \ninterventions\u201d, \u201cmanipulation and body-based methods\u201d, and/or \u201cenergy \ntherapies\u201d. Of these practices, the most common were yoga, reiki, the appli -\ncation of electromagnetic fields, salt water baths, acupuncture, hyperther -\nmia, and relaxation exercises.\nIn total, 81.4% of the CAM users started to use it after cancer diagno -\nsis (Table 2). The median duration of use was 4.5 months (range, 0-180 \nmonths).\nThe most common sources of information about CAM were relatives or \nfriends (Table 2). Four patients learned of CAM through a homeopath and \n3 through herbalisms.\nA total of 64.7% of the CAM users perceived some kind of impro -\nvement with its use (Table 2). One adverse effect was reported, which \nwas described as stomach acidity after taking a commercial preparation of \nechinacea and cat\u2019s claw. Of the patients who started using CAM after the \ncancer diagnosis, 52 (63%) reported that CAM was helping them in some \nway: 24 (29%) considered that CAM improved their physical and mental \nstrength, 20 (24.1%) thought that it helped to alleviate the adverse effects \nof treatment, 14 (16.9%) believed that it helped to strengthen their immune \nsystem, and 2 (2.4%) considered that it helped them fight cancer.\nCharacteristics that influence CAM use\nThe potential predictors of CAM use in relation to sociodemographic \nand clinical characteristics are shown in Table 3. Female gender was positi -\nvely associated with CAM use. Women were estimated to have 1.72 times \n(95%CI 1.06-2.80, P = 0.028) more risk of CAM use than men. Significant \ndifferences were found in CAM use by age. Taking age as a continuous \nvariable, it was found that CAM use decreased per completed year (OR: \n0.96; 95%CI 0.94-0.98; P<.001). The risk of CAM use in patients with \nsecondary education was double that of patients with no or primary educa -\ntion (95%CI 1.19-3.38; P = 0.009).\nAround half of the patients participating in clinical trials stated that they \nwere using CAM at the time of the study. However, no statistical difference \nwas found in CAM use between these patients and those not participating \nin trials (OR: 2.16; 95%CI 0.61-7 .62).Discussion\nLittle information is available on CAM use among people diagnosed \nwith cancer in Spain. The present study provides preliminary information on \nthe frequency of CAM use and the type of CAM used by patients receiving \nintravenous treatment. The justification of this study derives from the risk of \ninteraction between CAM and conventional treatment.\nThe prevalence of CAM use found in this study was slightly higher than that \nreferred by the only European multicentre study on CAM use in cancer patients \nfor the overall Spanish population (29.8%) 6. These data are in line with those of \nprevious studies on CAM in the field of oncology. In 1998, a systematic review of \n26 studies of cancer patients in 13 countries showed that the average prevalence \nof CAM use was 31%14. However, due to the growing popularity of CAM, higher \nrates of CAM use were to be expected in the present study. In fact, CAM use has \nbeen documented in 64% to 90% of cancer patients in the United States4,5 and \nclose to 50% in Asian countries15,16,17. This high prevalence may be related to the \nracial and cultural diversity of these countries, and the influence of Western and \nEastern CAM practices. Studies have found high levels of CAM use in Europe, \nranging from 45% to 51%9,18,19. However, an Italian study in which only current \nCAM use was assessed, as the present study, found a prevalence of 14%20.\nDirect comparisons between the results of this study and previous studies \nshould be made with caution, because of potential differences in sample type, \nsample size, methodology, and conceptualization (the definition and type of the -\nrapies considered as CAM). Due to staff shortages and time constraints, this study \nexcluded patients being treated with oral chemotherapy, but included cancer \npatients receiving intravenous treatment. The special diets or juices that were in -\ncluded in other studies 21,22 were not included as CAM. This study only included \nfood when it was taken as commercially capsules, tablets, and so on, or tra -\nditional Chinese medicine products15. High-protein nutritional supplements were \nalso excluded because they form part of the conventional health care of these \npatients. White, green, red, and black tea were not defined as CAM, given the \ndifficulty involved in determining whether they were used with therapeutic intent. \nThis aspect differs from other studies, which document the use of green tea as \nCAM4,5,6,15. These limitations in the definition of CAM, and the fact that their \ncurrent use alone was assessed, are possible causes of the lower prevalence \nfound in the present study.\nThe most common type of CAM used by the participants were products \ntaken by mouth, in contrast to practices related to the body or mind. The \nmost commonly used substances were herbs, natural remedies, and vitamins/\nminerals, as has already been documented in other studies11,19,23. This aspect \nreflects the attractiveness of \u201cnatural\u201d therapies and remedies to patients, but it \nis precisely these substances that may involve the greatest risk6. In fact, phar -\nmacokinetic interactions have been identified between certain herbs and natu -\nral products and chemotherapy: preclinical studies24-25 have found that garlic, \nginseng, echinacea, and soy are CYP450 inhibitors. Thus, they can decrease \nthe elimination of cytostatic drugs and increase their toxicity. In fact, garlic and \nechinacea were used by the study patients. Other substances used by the \npatients that interact with chemotherapeutic drugs were liquorice, reishi, radish, \nand ginger26. The most commonly used vitamin supplement was vitamin C, \nwhich is known to interact with cancer drugs such as methotrexate or imatinib27.\nThe majority of patients (81%) started CAM after cancer diagnosis. As \nfound in other studies6-7, the most important sources of information on CAM \nwere word-of-mouth or relatives and friends, whereas patients only rarely \nconsulted health professionals. It is clear that health care professionals need \nto increase their awareness and knowledge of CAM use, so that they can \nbecome the point of reference in the integral treatment of the patient. The \nhospital pharmacist can play an important role in this process, particularly in \nthe analysis of potential interactions between conventional and complemen -\ntary therapy. It would be useful to implement alert systems that include these \nproducts in pharmaceutical validation and dispensing software.\nOne-quarter of the patients using CAM claimed they did not feel any \nimprovement with CAM but continued to use it. The concept of \u201chope\u201d may \nbe a fundamental reason for the use of CAM6. The beneficial aspects of \nCAM use more frequently reported by the patients were similar to the main \nreasons for CAM use found in other studies: to obtain a good level of \ngeneral health, improve physical and emotional well-being, and boost the \nimmune system6 - 7, 28. Although the questionnaire contained specific items on \nthe effect of CAM, the improvements perceived by the patients could have \nbeen influenced by the effects of chemotherapy, given that both treatment \nmodalities were used simultaneously.Table 2.  Answers regarding the use of Complementary Medicine\nVariable n %\nBeginning of CAM use (n=102)\n Before the diagnosis\n After the diagnosis\n NN/NR16\n83\n315.6\n81.4\n3\nSources of information*\n Television\n Magazines\n Radio\n Internet\n Family/friends\n Health care professionals\u2020\n Other\n NN/NR0\n2\n1\n9\n70\n8\n19\n70\n2\n1\n8.8\n68.6\n7.8\n18.6\n6. 9\nPerceived effect (n=102)\n None\n Improvement\n Adverse effects\n NN/NR27\n66\n1\n826.5\n64.7\n1\n7.8\n* More than 1 source of information on Complementary Medicine may have been used.\n\u2020 Medical staff, pharmacists, and nurses.\nAbbreviations: NN/NR, not known/did not reply.\n004_10805- Uso de medicina complementaria en pacientes oncologicos.indd   592 24/08/2017   20:16593Farmacia Hospitalaria 2017\nl Vol. 41 l N\u00ba 5 l 589 - 600 l\nComplementary medicine use in cancer patients receiving intravenous antineoplastic treatment\nTable 3.  Socio-demographic and clinical characteristics influencing CAM use\nVariableCAM use \nOR (95%CI)* P value\nNO n (%) Yes n (%)\nGender\n Man\n Woman106 (74.1)\n108 (62.4)37 (25.9)\n65 (37.6)(reference)\n1.72 (1.06-2.80) 0.028\nAge\n \u2264 55 y\n > 55 y50 (53.2)\n164 (73.9)44 (46.8)\n58 (26.1)(reference)\n0.40 (0.24-0.66) <0.001\nPlace of residence\n Urban\n Rural117 (70.5)\n97 (64.7)49 (29.5)\n53 (35.3)(reference)\n1.31 (0.81-2.09) 0.270\nMarital status\n Single\n Married\n Partnered\n Divorced\n Widow/widower36 (76.6)\n148 (64.9)\n5 (55.6)\n7 (70.0)\n17 (81.0)11 (23.4)\n80 (35.1)\n4 (44.4)\n3 (30.0)\n4 (19.0)(reference)\n1.77 (0.85-3.67)\n2.62 (0.60-11.48)\n1.40 (0.31-6.36)\n0.77 (0.21-2.77)0.125\n0.202\n0.661\n0.689\nEducational level\n No/primary\n Secondary\u2021\n Higher\u00a7107 (74.3)\n72 (59.0)\n35 (70.0)37 (25.7)\n50 (41.0)\n15 (30.0)(reference)\n2.01 (1.19-3.38)\n1.24 (0.61-2.52)0.009\n0.554\nType of cancer\n Breast\n Colorectal\n Lung\n Other68 (66.7)\n55 (68.8)\n31 (70.5)\n60 (66.7)34 (33.3)\n25 (31.2)\n13 (29.5)\n30 (33.3)(reference)\n0.91 (0.49-1.70)\n0.84 (0.39-1.81)\n1.00 (0.55-1.82)0.766\n0.653\n1.000\nTime of diagnosis\n \u2264 12 mo\n 13-35 mo\n \u2265 36 mo107 (65.6)\n45 (62.5)\n62 (76.5)56 (34.4)\n27 (37.5)\n19 (23.5)(reference)\n1.15 (0.64-2.04)\n0.59 (0.32-1.08)0.642\n0.084\nCancer grade\n IV\n Other135 (66.8)\n79 (69.9)67 (33.2)\n34 (30.1)(reference)\n0.87 (0.53-1.43) 0.574\nSurgery\u2020\n No\n Yes68 (73.1)\n146 (65.8)25 (26.9)\n76 (34.2)(reference)\n1.42 (0.83-2.42) 0.203\nRadiotherapy\u2020\n No\n Yes114 (64.4)\n100 (72.5)63 (35.6)\n38 (27.5)(reference)\n0.69 (0.42-1.12) 0.129\nNo. treatment lines\n 1 line\n >1 lines104 (68.4)\n110 (67.1)48 (31.6)\n54 (32.9)(reference)\n1.06 (0.66-1.71) 0.798\n* Raw odds ratio used to analyse the association between potential predictors and CAM use.\n\u2020 The study included 315 patients who authorized access to their medical records.\n\u2021 Includes secondary education, intermediate and advanced vocational training, and baccalaureate.\n\u00a7 University education.\nAbbreviations: CAM, complementary and alternative medicine.\nThree variables were predictive of CAM use: female gender, young age, \nand secondary education. The first two variables have been identified as pre -\ndictors by other studies6,29. Increased CAM use has also been associated with \npatients with higher education6,8 and with advanced stages of the disease30.\nThis study may have some limitations. On the one hand, patients were as -\nked to indicate the type of CAM used by classifying it into a specific category \nin the questionnaire. Since it is common for patients to use more than 1 type of \nCAM, bias may have been present in relation to recall and knowledge of the \ntype of CAM. In order to minimize this possibility, the patients who were una -\nble to recall these details during the interview were contacted by telephone. \nA follow-up visit would have been useful to physically see the products used \nand thus classify them. However, due to time constraints, the researchers were \nunable to do so. On the other hand, the participation of two researchers in \nthe interviews may have caused interviewer bias due to the effect that different oral and body language may have on patient responses. In order to minimize \nthis possibility, both interviewers participated in designing the questionnaire, \nand agreed on the criteria for the definition of CAM and its classification.\nA significant number of the patients were using CAM at the same time \nas their conventional medical treatment. Given that CAM is mainly taken by \nmouth, there is a potential risk of CAM-chemotherapy interaction. As this as -\npect was not an objective of the present study the magnitude of this problem \nremains unknown. We believe that health care professionals need to become \naware of the importance of investigating CAM use among patients and to \nbe able to advise them. This study found a statistically significant association \nbetween CAM use and female gender, younger age, and secondary educa -\ntion. This finding could prove useful in identifying potential CAM users. Future \nstudies could investigate both the use of CAM in groups of patients with a \nspecific type of cancer and potential CAM-chemotherapy interactions.\n004_10805- Uso de medicina complementaria en pacientes oncologicos.indd   593 24/08/2017   20:16594Farmacia Hospitalaria 2017\nl Vol. 41 l N\u00ba 5 l 589 - 600 l\nRegina Juanbeltz et al.\nhealth professionals about complementary medicine. Significant predic -\ntors of CAM use were female gender, younger age, and secondary \neducation.\nRegardless of the position of health professionals toward comple -\nmentary medicine, this study demonstrates that patients make use of \nsuch treatment due to the physical-emotional impact of a diagnosis \nof cancer and its treatment. Given the prevalence of use of comple -\nmentary medicine and low number of consultations with healthcare \nprofessionals, it is clear that training in this field is needed such that \nthe medical professional can provide advice on the effectiveness \nof complementary medicine and on any contraindications. The role \nof the hospital pharmacist is relevant during the patient interview \nand when reviewing possible interactions between the preparations \nused and chemotherapy in order to ensure its safety and efficacy.\nBibliography\n1. Mao JJ, Palmer CS, Healy KE, Desai K, Amsterdam J. Complementary and alter -\nnative medicine use among cancer survivors: a population-based study. J Cancer \nS u r v i v.  2 011; 5 (1) :8 -17.\n2. Goldstein MS, Brown ER, Ballard-Barbash R, Morgenstern H, Bastani R, Lee J, et al. \nThe use of complementary and alternative medicine among California adults with \nand without cancer. Evid Based Complement Alternat Med. 2005;2(4):557-65.\n3. Yates JS, Mustian KM, Morrow GR, Gillies LJ, Padmanaban D, Atkins JN, et al. \nPrevalence of complementary and alternative medicine use in cancer patients \nduring treatment. Support Care Cancer. 2005;13(10):806-1 1.\n4. Anderson JG, Taylor AG. Use of complementary therapies for cancer symptom \nmanagement: results of the 2007 National Health Interview Survey. J Altern Com -\nplement Med. 2012;18(3):235-41.\n5. Rausch SM, Winegardner F, Kruk KM, Phatak V, Wahner-Roedler DL, Bauer B, \net al. Complementary and alternative medicine: use and disclosure in radiation \noncology community practice. Support Care Cancer. 201 1;19(4):521-9.\n6. Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, et al. \nPrevalence of complementary and alternative medicine use in cancer patients \nduring treatment. Ann Oncol. 2005;16(4):655-63.\n7. Helyer LK, Chin S, Chui BK, Fitzgerald B, Verma S, Rakovitch E, et al. The use of \ncomplementary and alternative medicines among patients with locally advanced \nbreast cancer--a descriptive study. BMC Cancer. 2006;6:39.\n8. Garland SN, Valentine D, Desai K, Li S, Langer C, Evans T, et al. Complementary \nand alternative medicine: use and disclosure in radiation oncology community \npractice. J Altern Complement Med. 2013;19(1 1):876-81.\n9. Berretta M, Della Pepa C, Tralongo P, Fulvi A, Martellotta F, Lleshi A, et al. Pre-\nvalence of complementary and alternative medicine use in cancer patients during \ntreatment. An Italian multicenter survey. Oncotarget. 2017;8(15):24401-14.\n10. Ernst E. Complementary cancer treatments: hope or hazard?. Clin Oncol. (R Coll \nRadiol). 1995;7(4):259-63.\n11. Huebner J, Micke O, Muecke R, Buentzel J, Prott FJ, Kleeberg U, et al. User rate of \ncomplementary and alternative medicine (CAM) of patients visiting a counseling \nfacility for CAM of a German comprehensive cancer center. Anticancer Res. \n2014;34(2):943-8.\n12. Block KI. Significance of natural product interactions in oncology. Integr Cancer \nTher. 2013;12(1):4-6.\n13. Bossaer JB, Odle BL. Probable etoposide interaction with Echinacea. J Diet Suppl. \n2012;9(2):90-5.\n14. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in \ncancer: a systematic review. Cancer. 1998;83(4):777-82.\n15. Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, et al. Preva -\nlence of complementary and alternative medicine use in cancer patients during \ntreatment. J Clin Oncol. 2005;23(12):2645-54.\n16. Nagashekhara M, Murthy V, Mruthyunjaya AT, Li Ann L. An Empirical Study on \nTraditional, Complementary and Alternative Medicine Usage among Malaysian \nCancer Patients. Asian Pac J Cancer Prev. 2015;16(15):6237-41.17. Oyunchimeg B, Hwang JH, Ahmed M, Choi S, Han D. Complementary and \nalternative medicine use among patients with cancer in Mongolia: a National \nhospital survey. BMC Complement Altern Med. 2017;17(1):858.\n18. Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S, et al. \nPrevalence of complementary and alternative medicine use in cancer patients \nduring treatment. Support Care Cancer. 2006;14(3):260-7 .\n19. Wortmann JK, Bremer A, Eich HT, Wortmann HP, Schuster A, Fuhner J, et \nal. Use of complementary and alternative medicine by patients with can -\ncer: a cross-sectional study at different points of cancer care. Ann Oncol. \n2016;33(7):858.\n20. Johannessen H, von Bornemann Hjelmborg J, Pasquarelli E, Fiorentini G, Di \nCostanzos F, Miccinesi G. Prevalence in the use of complementary medicine \namong cancer patients in Tuscany, Italy. Tumori. 2008;94(3):406-10.\n21. Perlman A, Lontok O, Huhmann M, Parrott JS, Simmons LA, Patrick-Miller L. \nPrevalence and correlates of postdiagnosis initiation of complementary and \nalternative medicine among patients at a comprehensive cancer center. J On -\ncol Pract. 2013;9(1):34-41.\n22. Pihlak R, Liivand R, Trelin O, Neissar H, Peterson I, Kivistik S, et al.  Com -\nplementary medicine use among cancer patients receiving radiotherapy and \nchemotherapy: methods, sources of information and the need for counselling. \nEur J Cancer Care. (Engl). 2014;23(2):249-54.\n23. Yarney J, Donkor A, Opoku SY, Yarney L, Agyeman-Duah I, Abakah AC, et \nal. Characteristics of users and implications for the use of complementary and \nalternative medicine in Ghanaian cancer patients undergoing radiotherapy \nand chemotherapy: a cross- sectional study. BMC Complement Altern Med. \n2013;13:16.\n24. Hardy ML. Dietary supplement use in cancer care: help or harm. Hematol \nOncol Clin North Am. 2008;22(4):581-617 .\n25. Lee CO. Herbs and cytotoxic drugs: recognizing and communicating poten -\ntially relevant interactions. J Oncol Pract. 2005;9(4):481-7 .\n26. Arslan D, Tural D, Akar E. Herbal administration and interaction of cancer \ntreatment. J Altern Complement Med. 2013;16(1 1):1466-76.\n2 7. Collado-Borrell R, Escudero-Vilaplana V, Romero-Jimenez R, Iglesias-Peinado \nI, Herranz-Alonso A, Sanjurjo-Saez M. Oral antineoplastic agent interactions \nwith medicinal plants and food: an issue to take into account. J Clin Oncol. \n2016;142(11):2319-30.\n28. Astin JA, Reilly C, Perkins C, Child WL, Susan GKBCF. Breast cancer pa -\ntients\u2019 perspectives on and use of complementary and alternative medicine: \na study by the Susan G. Komen Breast Cancer Foundation. J Clin Oncol. \n20 06;4(4):157- 69.\n29. Bott J. An analysis of paper-based sources of information on complementary \ntherapies. Complement Ther Clin Pract. 2007;13(1):53-62.\n30. Klafke N, Eliott JA, Wittert GA, Olver IN. Prevalence and predictors of com -\nplementary and alternative medicine (CAM) use by men in Australian cancer \noutpatient services. Ann Oncol. 2012;23(6):1571-8.Contribution to the scientific literature\nThe aim of this study was to determine the prevalence of com -\nplementary medicine use among cancer patients receiving medical \ntreatment with chemotherapy. To the best of our knowledge, this is the \nfirst study to investigate this topic in Spain. Although the prevalence of \nuse of complementary and alternative medicine (CAM) among such \npatients has been documented, most of this information comes from the \nUnited States. This study shows that one-third of the patients receiving \nintravenous chemotherapy in ambulatory treatment units were simulta -\nneously using other types of treatment generally taken by mouth (89%). \nThese treatments mainly comprised herbs and natural remedies. The \ndiversity of products was high because of the large number of ingre -\ndients included in each preparation. The high number of patients taking \nCAM contrasts with the low number of patients (8%) who consulted \n004_10805- Uso de medicina complementaria en pacientes oncologicos.indd   594 24/08/2017   20:16595Farmacia Hospitalaria 2017\nl Vol. 41 l N\u00ba 5 l 589 - 600 l\nComplementary medicine use in cancer patients receiving intravenous antineoplastic treatment\nVERSI\u00d3N ESPA\u00d1OLA\nIntroducci\u00f3n\nEl uso de Medicina Alternativa y Complementaria (MAC) entre los pa -\ncientes oncol\u00f3gicos es elevado y superior al de la poblaci\u00f3n general1-2. La \nmayor\u00eda de la informaci\u00f3n procede de Estados Unidos, donde los estudios \nmuestran un consumo de hasta el 90% en estos pacientes3-5. Sin embargo, \ndisponemos de pocos datos en Europa. En el a\u00f1o 2005 se llev\u00f3 a cabo \nun estudio europeo en el que participaron 14 pa\u00edses, con una prevalencia \nde empleo de MAC en pacientes oncol\u00f3gicos del 35,9%, siendo Espa\u00f1a \nel cuarto pa\u00eds de menor consumo (29,8%)6.\nSe ha asociado el uso de MAC a pacientes j\u00f3venes, mujeres, casa -\ndas, con alto nivel educativo e ingresos anuales6-7. En cuanto al tipo de \ndiagn\u00f3stico, es m\u00e1s habitual en pacientes con c\u00e1ncer de mama, pulm\u00f3n \ny gastrointestinal8,9. Algunos de los tipos de MAC m\u00e1s populares entre \nestos pacientes son los suplementos diet\u00e9ticos, productos de herboriste -\nr\u00eda, homeopat\u00eda, vitaminas y minerales10 -11. Todas ellas son pr\u00e1cticas de \nMAC que suponen la ingesta oral de ciertos productos, y podr\u00edan por \nello afectar a la seguridad terap\u00e9utica de los pacientes, ya que se han \ndescrito interacciones entre ciertas sustancias, principalmente plantas, y la \nquimioterapia12-13. \nEn nuestro medio se desconoce la prevalencia de empleo de MAC en \nlos pacientes diagnosticados de c\u00e1ncer y, en concreto, en aquellos que \nsiguen tratamiento, en los que resulta de especial inter\u00e9s por el riesgo de \ninteracci\u00f3n que puede existir. \nEl objetivo principal de este estudio es determinar la proporci\u00f3n de \npacientes oncol\u00f3gicos que utilizan medicina complementaria al tratamien -\nto antineopl\u00e1sico intravenoso prescrito de acuerdo a la pr\u00e1ctica cl\u00ednica \nhabitual. \nLos objetivos secundarios planteados son: analizar el tipo y tiempo de \nempleo de MAC, las fuentes de informaci\u00f3n empleadas, conocer los re -\nsultados percibidos por los pacientes acerca de los tratamientos comple -\nmentarios, y realizar una caracterizaci\u00f3n socio-demogr\u00e1fica y cl\u00ednica de la \npoblaci\u00f3n consumidora de MAC.\nM\u00e9todos\nDise\u00f1o y pacientes\nSe llev\u00f3 a cabo un estudio observacional, descriptivo y transversal, en \nel Hospital de D\u00eda de Oncolog\u00eda del centro de referencia de la Comunidad \nAut\u00f3noma de Navarra. \nSe invit\u00f3 a participar en el estudio a los pacientes citados a tratamiento \ndurante dos semanas consecutivas de marzo de 2015. Los criterios de in -\nclusi\u00f3n fueron: tener 18 a\u00f1os o m\u00e1s, un diagn\u00f3stico de c\u00e1ncer confirmado \ny estar recibiendo tratamiento antineopl\u00e1sico intravenoso en ese momento. \nSe excluyeron aquellos pacientes que presentaban dificultades ling\u00fc\u00edsticas \ntanto en la comprensi\u00f3n oral como escrita del cuestionario. \nSe solicit\u00f3 la firma del consentimiento informado por escrito a los par -\nticipantes, en la que autorizaban el acceso a la Historia Cl\u00ednica, y se les \nentreg\u00f3 una Hoja de Informaci\u00f3n con un tel\u00e9fono de contacto. \nLas variables estudiadas se obtuvieron mediante un cuestionario guiado \npor entrevista a pacientes, que se cumplimentaba en las salas de trata -\nmiento, y la Historia Cl\u00ednica Informatizada. El estudio se llev\u00f3 a cabo de \nacuerdo con la Declaraci\u00f3n de Helsinki as\u00ed como con la legislaci\u00f3n vigente \nen Espa\u00f1a (orden ministerial SAS/3470/2009, de estudios observaciona -\nles). El protocolo fue evaluado por el Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica \n(CEIC) de la Comunidad Aut\u00f3noma y clasificado por la Agencia Espa\u00f1ola \nde Medicamentos y Productos Sanitarios como un \u201cEstudio Posautorizaci\u00f3n \ncon Otros Dise\u00f1os diferentes al de seguimiento prospectivo\u201d (EPA-OD).\nCuestionario\nDebido a que no existe un cuestionario validado, se dise\u00f1\u00f3 tras una \nrevisi\u00f3n de la literatura y fue evaluado por un onc\u00f3logo, dos epidemi\u00f3logos \ny un farmac\u00e9utico cl\u00ednico (Figura 1). Constaba de 9 preguntas y recog\u00eda la \nsiguiente informaci\u00f3n:\n\u2022 Datos socio-demogr\u00e1ficos: sexo, edad, lugar de residencia, estado civil \ny nivel de estudios.\u2022 Preguntas sobre el empleo actual de MAC: tipo de MAC utilizada, \nmomento de inicio de MAC (previo o posterior al diagn\u00f3stico oncol\u00f3 -\ngico), tiempo consumiendo MAC, fuentes de informaci\u00f3n y resultados \npercibidos (ning\u00fan resultado, mejor\u00eda o efectos adversos).\nLos tipos de MAC se englobaron en dos grandes grupos, bas\u00e1ndose \nen si la medicina complementaria supon\u00eda ingerir alg\u00fan producto o no: \n\u201cIngesta oral de alg\u00fan producto\u201d u \u201cOtros\u201d. Si marcaban la casilla \u201cIngesta \noral\u201d, se ped\u00eda que identificasen si se trataba de productos homeop\u00e1ticos, \nhierbas, vitaminas y/o minerales o terapias naturales. No se consideraron \ncomo MAC los cambios en la dieta ni los alimentos, a excepci\u00f3n de los \nformulados comercialmente como c\u00e1psulas, comprimidos, etc. y los produc -\ntos de la medicina tradicional china, que fuesen tomados por el paciente \ncon intenci\u00f3n terap\u00e9utica. En el caso de rellenar la casilla \u201cOtros\u201d, se soli -\ncitaba que escribiesen de qu\u00e9 se trataba (por ejemplo yoga, osteopat\u00eda, \nacupuntura, campos electromagn\u00e9ticos, etc.) En ambos apartados, hab\u00eda \nun campo libre para poder hacer cualquier aclaraci\u00f3n. El \u00faltimo \u00edtem del \ncuestionario solicitaba un n\u00famero de tel\u00e9fono para que, en caso de autori -\nzaci\u00f3n, el investigador pudiese ampliar la informaci\u00f3n acerca del tipo de \nMAC empleada.\nPosteriormente, se recogieron datos cl\u00ednicos de los pacientes mediante \nla plataforma de Historia Cl\u00ednica Informatizada del Servicio Navarro de \nSalud:\n\u2022 Diagn\u00f3stico oncol\u00f3gico (tipo de tumor, estadio y momento del diag -\nn\u00f3stico).\n\u2022 N\u00famero de l\u00edneas de tratamiento oncol\u00f3gico recibidas.\n\u2022 Cirug\u00eda y/o Radioterapia como tratamiento del proceso.\nAn\u00e1lisis Estad\u00edstico\nSe emple\u00f3 el programa IBM SPSS v22 de Windows para realizar el \nan\u00e1lisis estad\u00edstico. Se llev\u00f3 a cabo un estudio descriptivo mediante an\u00e1lisis \nde frecuencias y proporciones (N\u00ba, %)  para las variables cualitativas, y \nmedidas de posici\u00f3n para las variables cuantitativas edad y tiempo de \nconsumo de MAC.\nSe analizaron los potenciales predictores de uso de MAC mediante \nregresi\u00f3n log\u00edstica simple. Se estimaron OR crudas y su  intervalo de con -\nfianza al 95%. \nResultados\nParticipantes\nDurante las dos semanas de muestreo, 539 personas fueron citadas \nen el Hospital de D\u00eda de Oncolog\u00eda para recibir tratamiento intravenoso. \nNo se administr\u00f3 a 58 de ellas (10,8%), de modo que no accedieron a \nlas salas en las que se estaba realizando el estudio, y a 108 personas no \nse les pudo localizar. Por lo tanto, el estudio se propuso a un total de 373 \npacientes. \nHubo 53 personas que libremente decidieron no ser incluidas y otras 4 \ncumpl\u00edan criterios de exclusi\u00f3n, debido a la imposibilidad de comprensi\u00f3n \ndel cuestionario por desconocimiento del idioma en tres pacientes y por \ndiagn\u00f3stico psiqui\u00e1trico en otro caso.\nLa muestra de este estudio se compone de 316 personas, lo que repre -\nsenta el 84,7% de los pacientes a los que se les propuso. Fue necesario \nrealizar llamadas telef\u00f3nicas para ampliar la informaci\u00f3n en 12 (3,8%) \ncasos.\nCaracter\u00edsticas sociodemogr\u00e1ficas y cl\u00ednicas\nLas caracter\u00edsticas sociodemogr\u00e1ficas y cl\u00ednicas de los pacientes se pre -\nsentan en la Tabla 1.\nUn total de 173 mujeres (54,7%) participaron en el estudio, y la edad \nmedia de los pacientes fue 61 a\u00f1os (24-85). Cerca de la mitad viv\u00eda en \nzona rural y casi tres cuartas partes de la poblaci\u00f3n estaban casados. El \n16% pose\u00eda titulaci\u00f3n Universitaria.\nEl diagn\u00f3stico oncol\u00f3gico m\u00e1s frecuente fue c\u00e1ncer de mama (32,3%), \nseguido de colorrectal y pulm\u00f3n. La mediana de tiempo transcurrido desde \nel diagn\u00f3stico de la enfermedad fue 12 meses (rango 0-266 meses). Un \n004_10805- Uso de medicina complementaria en pacientes oncologicos.indd   595 24/08/2017   20:16596Farmacia Hospitalaria 2017\nl Vol. 41 l N\u00ba 5 l 589 - 600 l\nRegina Juanbeltz et al.\ntotal de 222 pacientes (70%) hab\u00edan sido operados para tratar su tumor, \ny 138 (44%) hab\u00edan recibido radioterapia. Hubo 10 (3,2%) pacientes que \nparticipaban en ensayos cl\u00ednicos en el momento de su inclusi\u00f3n en el es -\ntudio.\nUso de MAC\nEl uso simult\u00e1neo de MAC y el tratamiento convencional con quimiote -\nrapia fue referido por 102 pacientes (32,3%). \nEl 89% de las personas que empleaban MAC tomaban oralmente \nalg\u00fan preparado. Los tipos de productos ingeridos con m\u00e1s frecuencia \nfueron plantas (n=60, 66%), seguido de terapias naturales (n=35, 38,5%), \nvitaminas/minerales (n=32, 35,2%) y homeopat\u00eda (n=16, 17 ,6%), respecti -\nvamente.\nSe contabilizaron 51 plantas diferentes. El 1 1,7% de los pacientes que \ntomaban plantas empleaba c\u00farcuma, que fue la m\u00e1s frecuente seguido de \nu\u00f1a de gato (8,3%), regaliz (8,3%), tomillo (8,3%), cardo mariano (6,7%), \nmelisa (6,7%) y equin\u00e1cea (5%). En el caso de terapias naturales, se conta -\nbilizaron 33 diferentes, siendo las m\u00e1s comunes hongos terap\u00e9uticos pro -\ncedentes de la medicina tradicional china (14,3%), lactobacillus (14,3%) , \njalea real (1 1,4%), prop\u00f3leo (1 1,4%), algas como spirulina y blue-green \n(8,6%),  sacharomyces (8,6%) , r\u00e1bano (5,7%), ajo negro (5,7%) y jengibre \n(5,7%) . De los pacientes que empleaban suplementos vitam\u00ednicos, el 50% \nusaba vitamina C, seguido de vitaminas del grupo B (31,3%) y vitamina E \n(18,8%). En cuanto a sales minerales, el zinc era empleado por el 21,9% de \nlos pacientes que las tomaban, seguido de magnesio (15,6%), bicarbonato \n(9,5%) y cobre (9,4%). Los productos homeop\u00e1ticos m\u00e1s comunes fueron el Suplemento Mineral Milagroso (MMS), consistente en clorito s\u00f3dico, cicuta \ny carcinosinum , que era utilizado por el 43,8% que usaba homeopat\u00eda, y \nlas Sales de Schussler (31,3%). \nDel total de pacientes que afirmaron utilizar MAC, 37 (36,3%) practica -\nban alguna terapia relacionada con la \u201cmedicina de la mente y el cuerpo\u201d, \n\u201cpr\u00e1cticas de manipulaci\u00f3n y basadas en el cuerpo\u201d y/o \u201cmedicina sobre \nenerg\u00eda\u201d. Entre \u00e9stas pr\u00e1cticas predominaron el yoga, reiki, aplicaci\u00f3n de \ncampos electromagn\u00e9ticos, ba\u00f1os de agua con sal, acupuntura, hiperter -\nmia y ejercicios de relajaci\u00f3n.\nEl 81,4% de los pacientes que empleaban MAC hab\u00eda comenzado a \nutilizarla tras el diagn\u00f3stico de la enfermedad (Tabla 2), siendo la mediana \nde tiempo de uso de 4,5 meses (0-180 meses). \nEl principal modo en el que conocieron la existencia de MAC (Tabla 2), \nfue trav\u00e9s de familiares o amigos. Hubo 4 pacientes que indicaron conocer \nlos productos a trav\u00e9s de un Home\u00f3pata y 3 a trav\u00e9s de Herborister\u00eda.\nEn relaci\u00f3n a los resultados percibidos acerca de la MAC (Tabla 2), el \n64,7% de las personas que la utilizaban afirmaron experimentar alg\u00fan tipo \nde beneficio con la misma. Se indic\u00f3 un efecto adverso, descrito como aci -\ndez de est\u00f3mago tras la ingesta de un preparado comercial de equin\u00e1cea \ny u\u00f1a de gato. Analizando exclusivamente los pacientes que comenzaron \na usar MAC a ra\u00edz del diagn\u00f3stico oncol\u00f3gico, 52 (63%) refer\u00edan que \nla MAC les estaba ayudando en alg\u00fan aspecto: 24 (29%) consideraban \nque les aportaba fortaleza f\u00edsica y ps\u00edquica, 20 (24,1%) que les ayudaba \na paliar los efectos secundarios del tratamiento, 14 (16,9%) que estaba \ncontribuyendo a fortalecer el sistema inmunitario y 2 (2,4%) a luchar contra \nel c\u00e1ncer.Figura 1.  Cuestionario sobre pr\u00e1cticas de medicina alternativa y complementaria.CUESTIONARIO SOBRE PR\u00c1CTICAS DE MEDICINA ALTERNATIVA Y  \nCOMPLEMENTARIA\nSe le solicita que responda de forma voluntaria y confidencial a esta encuesta.\nMarque con una \u201cX\u201d la casilla que considere oportuno.\nFecha de nacimiento:  ....................  Lugar de residencia:  ..........................\nSexo:\nEstado civil:\nNivel de estudios:\n\u00bfACTUALMENTE utiliza alguna medicina alternativa o complementaria aparte del  \ntratamiento que recibe en este Servicio de Hospital de D\u00eda? \nPor favor, indique cu\u00e1l (puede marcar m\u00e1s de una)Var\u00f3n Mujer\n  \nSoltero/a Casado/a Pareja de hecho Divorciado/a Viudo/a\n  \nNing\u00fan resultado Mejor\u00eda Efectos adversos\n  Sin estudios Primaria Secundaria BachilleratoGrado  \nmedio/superiorUniversitarios\n  \n Ninguna\n Ingesta oral de alg\u00fan producto:\n Homeopat\u00eda\n Hierbas medicinales\n Complejos vitam\u00ednicos y/o minerales\n  Ingesta de terapias \u201cnaturales\u201d: veneno de escorpi\u00f3n, cart\u00edlago \nde tibur\u00f3n, mu\u00e9rdago, hongos terap\u00e9uticos, etc.\nNOMBRE DE LOS PRODUCTOS QUE UTILIZA (si lo recuerda):\n .....................................................................................................\n Otros: yoga, osteopat\u00eda, acupuntura, campos electromagn\u00e9ticos, aromaterapia\n ................................................................................................................En su caso, indique cu\u00e1ndo inici\u00f3 el consumo de medicina alternativa:\n ANTES del diagn\u00f3stico de mi enfermedad oncol\u00f3gica\n A RA\u00cdZ del diagn\u00f3stico de mi enfermedad oncol\u00f3gica\nFECHA APROXIMADA del inicio de medicina alternativa o complementaria:\n .........................................................................................................\nEn su caso, indique cu\u00e1l es la fuente que le ha permitido obtener informaci\u00f3n sobre \n\u00e9sta medicina complementaria:\nTV  Revistas   Radio   Internet  \nFamiliares/amigos   M\u00e9dico   Farmac\u00e9utico  \nOtros:  ........................................................................................................\n\u00bfCu\u00e1l ha sido el resultado que usted ha obtenido con esta/s medicinas alternativas \no complementarias?\nY en caso de haber notado mejor\u00eda, indique en qu\u00e9 aspectos le ha ayudado:\n...................................................................................................................\n...................................................................................................................\n...................................................................................................................\nEn caso de haberle causado alg\u00fan efecto adverso, por favor, indique cu\u00e1l ha sido:\n...................................................................................................................\n...................................................................................................................\n...................................................................................................................\n  Autorizo a que un investigador del estudio me llame por tel\u00e9fono en caso \nde necesitar ampliar la informaci\u00f3n sobre el uso de medicina alternativa.\nTel\u00e9fono:  ...........................................................................................\nMuchas gracias por su colaboraci\u00f3n.\n004_10805- Uso de medicina complementaria en pacientes oncologicos.indd   596 24/08/2017   20:16597Farmacia Hospitalaria 2017\nl Vol. 41 l N\u00ba 5 l 589 - 600 l\nComplementary medicine use in cancer patients receiving intravenous antineoplastic treatment\nCaracter\u00edsticas que influyen en el empleo de MAC\nEn la Tabla 3 se describen los potenciales predictores de uso de MAC \nteniendo en cuenta las caracter\u00edsticas sociodemogr\u00e1ficas y cl\u00ednicas estu -\ndiadas. El sexo femenino se asoci\u00f3 de manera positiva con el uso de \nMAC, de manera que se estim\u00f3 que las mujeres ten\u00edan 1,72 veces (IC95% \n1,06-2,80; p=0,028) m\u00e1s riesgo de usar MAC que los hombres. La edad \ntambi\u00e9n mostr\u00f3 diferencias significativas en el uso de MAC. Teniendo en \ncuenta la edad como variable continua, \u00e9sta mostr\u00f3 un consumo decrecien -\nte de MAC por a\u00f1o cumplido (OR: 0,96 IC95% 0,94-0,98; p<0,001). El \nriesgo de empleo de MAC fue doble en los pacientes con estudios medios \nrespecto a los que carec\u00edan de estudios o ten\u00edan estudios b\u00e1sicos (IC95% \n1,19-3,38; p=0,009).La mitad de los pacientes que formaban parte de ensayos cl\u00ednicos afir -\nmaron utilizar MAC en el momento del estudio, sin encontrar diferencias \nestad\u00edsticamente significativas en el uso de MAC respecto a los pacientes \nque no participaban en ensayos (OR: 2,16 IC95% 0,61-7 ,62).\nDiscusi\u00f3n\nSe dispone de poca informaci\u00f3n acerca del uso de MAC entre las per -\nsonas diagnosticadas de c\u00e1ncer en Espa\u00f1a. El trabajo actual aporta una \nevidencia inicial acerca de la frecuencia de empleo de \u00e9stas medicinas \ncomplementarias y los tipos de pr\u00e1cticas utilizadas. En concreto, lo hace en \naquellos pacientes que reciben tratamiento intravenoso, en los que puede \nexistir riesgo de interacci\u00f3n entre la MAC y el mismo. \nLa prevalencia de consumo de MAC en esta poblaci\u00f3n fue ligeramente \nsuperior a la referida para la poblaci\u00f3n global espa\u00f1ola (29,8%), en el \n\u00fanico estudio multic\u00e9ntrico europeo sobre MAC en pacientes oncol\u00f3gicos \nque existe hasta la actualidad6. Son datos consistentes con resultados pre -\nvios de estudios realizados sobre MAC en el campo de la oncolog\u00eda. En \nel a\u00f1o 1998 se llev\u00f3 a cabo una revisi\u00f3n sistem\u00e1tica de 26 trabajos con \npacientes oncol\u00f3gicos en 13 pa\u00edses, y mostr\u00f3 una media de consumo del \n31%14. Sin embargo, debido a la creciente popularidad de la MAC se \npod\u00eda esperar obtener tasas de consumo superiores en este trabajo. De he -\ncho, en poblaci\u00f3n norteamericana se han documentado cifras de empleo \nde MAC del 64-90% en pacientes oncol\u00f3gicos4,5, y en pa\u00edses asi\u00e1ticos \nson cercanas al 50%15,16,17. Estas elevadas cifras de prevalencia pueden \nrelacionarse con la diversidad racial y cultural presente en estos pa\u00edses, \ny verse influenciadas tanto por las pr\u00e1cticas de MAC occidentales como \norientales. A nivel europeo, tambi\u00e9n se han encontrado cifras elevadas de \nuso de MAC, entre el 45-51%9,18,19. Sin embargo, en un estudio italiano \nque preguntaba exclusivamente por el uso actual de MAC, al igual que en \nnuestro caso, la cifra descend\u00eda al 14%20. \nLa comparaci\u00f3n directa de los resultados de este trabajo con estudios \nprevios debe hacerse con precauci\u00f3n, ya que pueden existir diferencias en \nel tipo y tama\u00f1o de muestra, metodol\u00f3gicas, y conceptuales (definici\u00f3n y \ntipo de terapias consideradas como MAC). En este estudio no se incluyeron \na los pacientes oncol\u00f3gicos que no estaban siendo tratados ni a los que \nsegu\u00edan tratamiento con quimioterapia oral, por motivos de limitaci\u00f3n de \npersonal y temporal. No se incluyeron como MAC las dietas especiales \nni zumos especiales contemplados por otros autores21,22, consider\u00e1ndose \ns\u00f3lo aquellos alimentos formulados comercialmente como c\u00e1psulas, com -\nprimidos, etc. o productos de la medicina tradicional china15. Tampoco Tabla 1.  Caracter\u00edsticas sociodemogr\u00e1ficas y cl\u00ednicas de los pacientes\nVariable n %\nSexo\n Mujer 173 54,7\nLugar de residencia\n Urbano\n Rural166\n15052,5\n47,5\nEstado civil\n Soltero/a\n Casado/a\n Pareja de hecho\n Divorciado/a\n Viudo/a\n Desconocido47\n228\n9\n10\n21\n114,9\n72,2\n2,8\n3,2\n6,6\n0,3\nEdad\n \u2264 55 a\u00f1os\n > 55 a\u00f1os94\n22229,7\n70,3\nNivel educativo\n Sin estudios o b\u00e1sicos\n Estudios Medios*\n Estudios Superiores\u2020144\n122\n5045,6\n38,6\n15,8\nTipo de c\u00e1ncer\n Mama\n Colorrectal\n Pulm\u00f3n\n Ginecol\u00f3gico\n Cabeza-cuello\n G\u00e1strico\n P\u00e1ncreas\n Otros\u2021\n Desconocido102\n80\n44\n20\n15\n11\n10\n32\n232,3\n25,3\n13,9\n6,3\n4,7\n3,5\n3,2\n10,2\n0,6\nEstadio enfermedad\u00a7\n I\n II\n III\n IV\n Desconocido34\n42\n37\n202\n110,8\n13,3\n11,7\n63,9\n0,3\nN\u00ba l\u00edneas tratamiento\u01c1\n 1\n 2-3\n \u2265 4\n Desconocido152\n115\n48\n148,1\n36,4\n15,2\n0,3\nTotal 316 100\n* Se incluyen estudios de Secundaria, Grado Formativo Medio/Superior y Bachillerato.\n\u2020  Estudios Universitarios.\n\u2021  Tumores con una prevalencia inferior a 10 pacientes en la muestra a estudio.\n\u00a7  Estadio en el momento de inclusi\u00f3n en el estudio. Basado en la clasificaci\u00f3n \nTNM del \u201cAmerican Joint Committee on Cancer\u201d (AJCC). Disponible en: https://\ncancerstaging.org/ \n\u01c1  Tratamiento quimioter\u00e1pico, inmuno-oncol\u00f3gico y hormonal.Tabla 2.  Respuestas relativas al uso de Medicina Complementaria\nVariable n %\nMomento de inicio (n=102)\n Antes de enfermedad\n A ra\u00edz de enfermedad\n NS/NC16\n83\n315,6\n81,4\n3\nFuentes de informaci\u00f3n* \n Televisi\u00f3n\n Revistas \n Radio\n Internet\n Familia/amigos\n Profesionales sanitarios\u2020\n Otros\n NS/NC0\n2\n1\n9\n70\n8\n19\n70\n2\n1\n8,8\n68,6\n7,8\n18,6\n6, 9\nResultado percibido (n=102)\n Ninguno\n Mejor\u00eda\n Efectos adversos\n NS/NC27\n66\n1\n826,5\n64,7\n1\n7,8\n*  M\u00e1s de una fuente de informaci\u00f3n sobre Medicina Complementaria pudo ser \nempleada.\n\u2020  Personal m \u00e9dico, farmac\u00e9utico y enfermer\u00eda.\nAbreviaturas: NS/NC, no sabe o no contesta.\n004_10805- Uso de medicina complementaria en pacientes oncologicos.indd   597 24/08/2017   20:16598Farmacia Hospitalaria 2017\nl Vol. 41 l N\u00ba 5 l 589 - 600 l\nRegina Juanbeltz et al.\nse tuvieron en cuenta los batidos hiperproteicos, ya que forman parte del \ncuidado m\u00e9dico habitual de estos pacientes. En cuanto a las plantas con -\nsideradas, cabe se\u00f1alar que no se definieron como MAC el t\u00e9 blanco, t\u00e9 \nverde, t\u00e9 rojo y t\u00e9 negro, ante la dificultad que supon\u00eda identificar si su uso \nten\u00eda una intenci\u00f3n terap\u00e9utica. Esto se diferencia de otros estudios, en los \nque se documenta el uso de t\u00e9 verde como MAC4,5,6,15. Estas limitaciones \nen la definici\u00f3n de MAC, y el hecho de evaluar exclusivamente su uso en el \nmomento actual, son posibles causas de la menor prevalencia encontrada \nen el presente estudio.\nLos tipos de MAC m\u00e1s utilizados en la muestra supon\u00edan un consumo \noral de productos, frente a la realizaci\u00f3n de pr\u00e1cticas relacionadas con el \ncuerpo o la mente. Las sustancias m\u00e1s empleadas fueron plantas, terapias \nnaturales y vitaminas/minerales, como ya se ha documentado en otros estudios11,19,23. Este aspecto refleja el atractivo que tienen las terapias y \nremedios \u201cnaturales\u201d para los pacientes, pero son precisamente estas sus -\ntancias las que entra\u00f1an mayor riesgo6. De hecho, han sido identificadas \ninteracciones farmacocin\u00e9ticas entre ciertas hierbas y productos naturales \ncon la quimioterapia: el ajo, gingseng, equin\u00e1cea y la soja son inhibidores \ndel CYP450 en estudios precl\u00ednicos24-25, por lo que pueden disminuir la \neliminaci\u00f3n de los f\u00e1rmacos citost\u00e1ticos e incrementar como consecuencia \nsu toxicidad. Precisamente el ajo y la equin\u00e1cea fueron productos utilizados \npor los pacientes del estudio. Otras sustancias utilizadas y que interaccio -\nnan con f\u00e1rmacos quimioter\u00e1picos son: regaliz, reishi, r\u00e1bano y jengibre26. \nLa suplementaci\u00f3n vitam\u00ednica m\u00e1s frecuente fue la vitamina C, para la que \nse han descrito interacciones con agentes antineopl\u00e1sicos como metotrexa -\nto o imatinib27.Tabla 3.  Caracter\u00edsticas socio-demogr\u00e1ficas y cl\u00ednicas influyentes en el uso de MAC\nVariableConsumo MAC\nOR (IC 95%)* P valor\nNO n (%) SI n (%)\nSexo\n Var\u00f3n\n Mujer106 (74,1)\n108 (62,4)37 (25,9)\n65 (37,6)(referencia)\n1,72 (1,06-2,80) 0,028\nEdad\n \u2264 55 a\u00f1os\n > 55 a\u00f1os50 (53,2)\n164 (73,9)44 (46,8)\n58 (26,1)(referencia)\n0,40 (0,24-0,66) <0,001\nLugar de residencia\n Urbano\n Rural117 (70,5)\n97 (64,7)49 (29,5)\n53 (35,3)(referencia)\n1,31 (0,81-2,09) 0,270\nEstado civil\u2020\n Soltero/a\n Casado/a\n Pareja de hecho\n Divorciado/a\n Viudo/a36 (76,6)\n148 (64,9)\n5 (55,6)\n7 (70,0)\n17 (81,0)11 (23,4)\n80 (35,1)\n4 (44,4)\n3 (30,0)\n4 (19,0)(referencia)\n1,77 (0,85-3,67)\n2,62 (0,60-11,48)\n1,40 (0,31-6,36)\n0,77 (0,21-2,77)0,125\n0,202\n0,661\n0,689\nNivel educativo\n Sin estudios o b\u00e1sicos\n Estudios medios\u2021\n Estudios superiores\u00a7107 (74,3)\n72 (59,0)\n35 (70,0)37 (25,7)\n50 (41,0)\n15 (30,0)(referencia)\n2,01 (1,19-3,38)\n1,24 (0,61-2,52)0,009\n0,554\nTipo de tumor\n Mama\n Colorrectal\n Pulm\u00f3n\n Resto68 (66,7)\n55 (68,8)\n31 (70,5)\n60 (66,7)34 (33,3)\n25 (31,2)\n13 (29,5)\n30 (33,3)(referencia)\n0,91 (0,49-1,70)\n0,84 (0,39-1,81)\n1,00 (0,55-1,82)0,766\n0,653\n1,000\nTiempo diagn\u00f3stico\n \u2264 12 meses\n 13-35 meses\n \u2265 36 meses107 (65,6)\n45 (62,5)\n62 (76,5)56 (34,4)\n27 (37,5)\n19 (23,5)(referencia)\n1,15 (0,64-2,04)\n0,59 (0,32-1,08)0,642\n0,084\nEstadio oncol\u00f3gico\n IV\n Resto135 (66,8)\n79 (69,9)67 (33,2)\n34 (30,1)(referencia)\n0,87 (0,53-1,43) 0,574\nCirug\u00eda\u2020\n No\n S\u00ed68 (73,1)\n146 (65,8)25 (26,9)\n76 (34,2)(referencia)\n1,42 (0,83-2,42) 0,203\nRadioterapia\u2020\n No\n S\u00ed114 (64,4)\n100 (72,5)63 (35,6)\n38 (27,5)(referencia)\n0,69 (0,42-1,12) 0,129\nN\u00ba l\u00edneas tratamiento\n 1 l\u00ednea\n > 1 l\u00ednea104 (68,4)\n110 (67,1)48 (31,6)\n54 (32,9)(referencia)\n1,06 (0,66-1,71) 0,798\n*  Odds ratio cruda para estudiar la asociaci\u00f3n entre predictores de inter\u00e9s y uso de MAC.\n\u2020  Incluidos en el an\u00e1lisis 315 pacientes que autorizaron el acceso a su Historia Cl\u00ednica.\n\u2021  Se incluyen estudios de Secundaria, Grado Formativo Medio/Superior y Bachillerato.\n\u00a7  Estudios Universitarios.\nAbreviaturas: MAC, medicina alternativa y complementaria.\n004_10805- Uso de medicina complementaria en pacientes oncologicos.indd   598 24/08/2017   20:16599Farmacia Hospitalaria 2017\nl Vol. 41 l N\u00ba 5 l 589 - 600 l\nComplementary medicine use in cancer patients receiving intravenous antineoplastic treatment\nLa mayor\u00eda de pacientes (81%) comenzaron la MAC tras el diagn\u00f3stico \noncol\u00f3gico. Sin embargo, el boca a boca de familiares y amigos parece \nser la fuente m\u00e1s importante, al igual que en otros estudios6-7, siendo la con -\nsulta al profesional sanitario poco frecuente. Se hace patente la necesidad \nde concienciaci\u00f3n y formaci\u00f3n de los profesionales sanitarios en el uso de \nMAC, para que puedan llegar a ser el referente en el tratamiento integral del \npaciente. En este aspecto el farmac\u00e9utico hospitalario puede desarrollar una \nlabor importante, especialmente en el an\u00e1lisis de interacciones potenciales \nentre el tratamiento convencional y complementario. Podr\u00eda ser de utilidad la \nimplantaci\u00f3n de sistemas de alerta que contemplen estos productos en los \nprogramas inform\u00e1ticos de validaci\u00f3n y dispensaci\u00f3n farmac\u00e9utica.\nUna cuarta parte de los pacientes que usaban MAC afirmaba no sentir \nninguna mejor\u00eda con la misma. A pesar de ello, segu\u00edan emple\u00e1ndola; \nquiz\u00e1 el concepto de \u201cesperanza\u201d pueda ser fundamental en la raz\u00f3n que \ncontribuya al uso de MAC6. Los aspectos beneficiosos m\u00e1s indicados por \nlos pacientes guardan relaci\u00f3n con las principales razones que motivan a \nusar MAC en otros estudios: otorgar buen estado de salud general, bien -\nestar f\u00edsico y emocional y fortalecer el sistema inmunitario6 - 7, 28. A pesar de \nque en el cuestionario se preguntaba espec\u00edficamente por los resultados \nobtenidos con la MAC, la mejor\u00eda percibida por los pacientes podr\u00eda estar \ninfluenciada por los efectos del tratamiento, debido a que la MAC se em -\npleaba a la vez que la quimioterapia.\nHubo tres variables predictoras del uso de MAC: ser mujer, ser joven \ny tener estudios medios. Las dos primeras se han identificado en otros \ntrabajos6,29. Sin embargo, tambi\u00e9n se ha asociado el mayor empleo de \nMAC a pacientes con estudios superiores6,8 y a estadios avanzados de la \nenfermedad30. \nEn este estudio pudo haber ciertas limitaciones. A los pacientes se les \nsolicitaba indicar en el cuestionario el tipo de MAC que empleaban, cla -\nsific\u00e1ndolo en una determinada categor\u00eda. Puesto que es frecuente que \nlos pacientes utilicen m\u00e1s de un tipo de MAC, puede haber sesgos en \nrelaci\u00f3n al recuerdo y al conocimiento del tipo de MAC. Con la intenci\u00f3n \nde minimizarlo, se llevaron a cabo llamadas telef\u00f3nicas a pacientes que no \neran capaces de recordarlo en el momento de la entrevista. Hubiera sido \ninteresante hacer una visita de seguimiento presencial para ver f\u00edsicamente \nlos productos utilizados y poder categorizarlos. Debido a un problema tem -\nporal, no fue posible hacerlo en este estudio. Por otro lado, la participaci\u00f3n \nde dos investigadores en las entrevistas a pacientes implica que pueda \nhaber sesgo del entrevistador, debido a la influencia que pueda tener el \ndiferente modo de comunicaci\u00f3n oral y corporal sobre las respuestas del \npaciente. Para minimizarlo ambos entrevistadores participaron en el dise\u00f1o \ndel cuestionario, y consensuaron criterios en la definici\u00f3n de MAC y su \nclasificaci\u00f3n.   \nUn n\u00famero importante de pacientes en este estudio usaron MAC al \nmismo tiempo que el tratamiento m\u00e9dico habitual. Debido a que la MAC se basaba fundamentalmente en una ingesta oral de sustancias, existe un \nriesgo potencial de interacci\u00f3n con la quimioterapia. Al no ser un obje -\ntivo del presente estudio, desconocemos la magnitud de este problema. \nConsideramos necesario concienciar a los profesionales sanitarios sobre \nla importancia de indagar sobre el empleo de MAC entre los pacientes y \npoder aconsejarles sobre ello. De acuerdo a este estudio, las mujeres, los \nj\u00f3venes y las personas con estudios medios son los que m\u00e1s emplean MAC \nde manera estad\u00edsticamente significativa, lo cual puede resultar de ayuda \npara identificar al potencial usuario de la misma. Ser\u00eda interesante realizar \nfuturos trabajos para estudiar el uso de MAC en grupos de pacientes con \nun tipo de c\u00e1ncer concreto, e indagar en las posibles interacciones entre la \nMAC y la quimioterapia.\nAportaci\u00f3n a la literatura cient\u00edfica\nEste es el primer estudio realizado en Espa\u00f1a, seg\u00fan nuestro conoci -\nmiento, que analiza la frecuencia de uso de medicina complementaria \nentre los pacientes oncol\u00f3gicos que reciben tratamiento m\u00e9dico con \nquimioterapia. Se ha documentado un uso frecuente de medicina al -\nternativa y complementaria entre estos pacientes, pero la mayor\u00eda de \nla informaci\u00f3n procede de pa\u00edses norteamericanos. En este trabajo se \nobserva que un tercio de los pacientes que acuden a Hospital de D\u00eda \na recibir quimioterapia intravenosa emplean simult\u00e1neamente otro tipo \nde pr\u00e1cticas, en su mayor\u00eda a base de ingesta de sustancias (89%), \nsobre todo plantas y terapias naturales. La diversidad de este tipo de \nproductos fue importante, por el elevado contenido de componentes \ndiferentes en un mismo preparado. Este aspecto contrasta con la es -\ncasa consulta al profesional sanitario acerca de la medicina comple -\nmentaria, ya que solo el 8% de los pacientes refiri\u00f3 haber obtenido \ninformaci\u00f3n a partir del mismo. Los factores que se asociaron al uso \nde medicina complementaria fueron el sexo (mujer), la edad y el nivel \neducativo (estudios medios).\nIndependientemente del posicionamiento de los profesionales sa -\nnitarios en el \u00e1mbito de la medicina complementaria, este trabajo de -\nmuestra que los pacientes la emplean, ante el impacto f\u00edsico-emocional \nque conlleva el diagn\u00f3stico y tratamiento oncol\u00f3gico. Debido a la \nelevada prevalencia de estas pr\u00e1cticas y a la escasa consulta observa -\nda al profesional sanitario, es importante la formaci\u00f3n en este \u00e1mbito, \npara que el profesional pueda llegar a ser un referente en el consejo \nsobre la efectividad y contraindicaci\u00f3n de ciertos usos de medicina \ncomplementaria. El papel del farmac\u00e9utico hospitalario es relevante en \nla entrevista al paciente y la revisi\u00f3n de las posibles interacciones entre \nlas sustancias empleadas y la quimioterapia, con el fin de garantizar \nsu seguridad y eficacia.\nBibliograf\u00eda\n1. Mao JJ, Palmer CS, Healy KE, Desai K, Amsterdam J. Complementary and alter -\nnative medicine use among cancer survivors: a population-based study. J Cancer \nS u r v i v.  2 011; 5 (1) :8 -17.\n2. Goldstein MS, Brown ER, Ballard-Barbash R, Morgenstern H, Bastani R, Lee \nJ, et al. The use of complementary and alternative medicine among Califor -\nnia adults with and without cancer. Evid Based Complement Alternat Med. \n2005;2(4):557-65.\n3. Yates JS, Mustian KM, Morrow GR, Gillies LJ, Padmanaban D, Atkins JN, et al. \nPrevalence of complementary and alternative medicine use in cancer patients \nduring treatment. Support Care Cancer. 2005;13(10):806-1 1.\n4. Anderson JG, Taylor AG. Use of complementary therapies for cancer symptom \nmanagement: results of the 2007 National Health Interview Survey. J Altern Com -\nplement Med. 2012;18(3):235-41.\n5. Rausch SM, Winegardner F, Kruk KM, Phatak V, Wahner-Roedler DL, Bauer B, \net al. Complementary and alternative medicine: use and disclosure in radiation \noncology community practice. Support Care Cancer. 201 1;19(4):521-9.\n6. Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, et al. \nPrevalence of complementary and alternative medicine use in cancer patients \nduring treatment. Ann Oncol. 2005;16(4):655-63.\n7. Helyer LK, Chin S, Chui BK, Fitzgerald B, Verma S, Rakovitch E, et al. The use of \ncomplementary and alternative medicines among patients with locally advanced \nbreast cancer--a descriptive study. BMC Cancer. 2006;6:39.8. Garland SN, Valentine D, Desai K, Li S, Langer C, Evans T, et al. Complementary \nand alternative medicine: use and disclosure in radiation oncology community \npractice. J Altern Complement Med. 2013;19(1 1):876-81.\n9. Berretta M, Della Pepa C, Tralongo P, Fulvi A, Martellotta F, Lleshi A, et al. Pre-\nvalence of complementary and alternative medicine use in cancer patients during \ntreatment. An Italian multicenter survey. Oncotarget. 2017;8(15):24401-14.\n10. Ernst E. Complementary cancer treatments: hope or hazard?. Clin Oncol. (R Coll \nRadiol). 1995;7(4):259-63.\n11. Huebner J, Micke O, Muecke R, Buentzel J, Prott FJ, Kleeberg U, et al. User rate of \ncomplementary and alternative medicine (CAM) of patients visiting a counseling \nfacility for CAM of a German comprehensive cancer center. Anticancer Res. \n2014;34(2):943-8.\n12. Block KI. Significance of natural product interactions in oncology. Integr Cancer \nTher. 2013;12(1):4-6.\n13. Bossaer JB, Odle BL. Probable etoposide interaction with Echinacea. J Diet Suppl. \n2012;9(2):90-5.\n14. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in \ncancer: a systematic review. Cancer. 1998;83(4):777-82.\n15. Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, et al. Preva -\nlence of complementary and alternative medicine use in cancer patients during \ntreatment. J Clin Oncol. 2005;23(12):2645-54.\n004_10805- Uso de medicina complementaria en pacientes oncologicos.indd   599 24/08/2017   20:16600Farmacia Hospitalaria 2017\nl Vol. 41 l N\u00ba 5 l 589 - 600 l\nRegina Juanbeltz et al.\n16. Nagashekhara M, Murthy V, Mruthyunjaya AT, Li Ann L. An Empirical Study on \nTraditional, Complementary and Alternative Medicine Usage among Malaysian \nCancer Patients. Asian Pac J Cancer Prev. 2015;16(15):6237-41.\n17. Oyunchimeg B, Hwang JH, Ahmed M, Choi S, Han D. Complementary and \nalternative medicine use among patients with cancer in Mongolia: a National \nhospital survey. BMC Complement Altern Med. 2017;17(1):858.\n18. Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S, et al. \nPrevalence of complementary and alternative medicine use in cancer patients \nduring treatment. Support Care Cancer. 2006;14(3):260-7 .\n19. Wortmann JK, Bremer A, Eich HT, Wortmann HP, Schuster A, Fuhner J, et \nal. Use of complementary and alternative medicine by patients with can -\ncer: a cross-sectional study at different points of cancer care. Ann Oncol. \n2016;33(7):858.\n20. Johannessen H, von Bornemann Hjelmborg J, Pasquarelli E, Fiorentini G, Di \nCostanzos F, Miccinesi G. Prevalence in the use of complementary medicine \namong cancer patients in Tuscany, Italy. Tumori. 2008;94(3):406-10.\n21. Perlman A, Lontok O, Huhmann M, Parrott JS, Simmons LA, Patrick-Miller L. \nPrevalence and correlates of postdiagnosis initiation of complementary and \nalternative medicine among patients at a comprehensive cancer center. J On -\ncol Pract. 2013;9(1):34-41.\n22. Pihlak R, Liivand R, Trelin O, Neissar H, Peterson I, Kivistik S, et al.  Com -\nplementary medicine use among cancer patients receiving radiotherapy and \nchemotherapy: methods, sources of information and the need for counselling. \nEur J Cancer Care. (Engl). 2014;23(2):249-54.23. Yarney J, Donkor A, Opoku SY, Yarney L, Agyeman-Duah I, Abakah AC, et \nal. Characteristics of users and implications for the use of complementary and \nalternative medicine in Ghanaian cancer patients undergoing radiotherapy \nand chemotherapy: a cross- sectional study. BMC Complement Altern Med. \n2013;13:16.\n24. Hardy ML. Dietary supplement use in cancer care: help or harm. Hematol \nOncol Clin North Am. 2008;22(4):581-617 .\n25. Lee CO. Herbs and cytotoxic drugs: recognizing and communicating poten -\ntially relevant interactions. J Oncol Pract. 2005;9(4):481-7 .\n26. Arslan D, Tural D, Akar E. Herbal administration and interaction of cancer \ntreatment. J Altern Complement Med. 2013;16(1 1):1466-76.\n2 7. Collado-Borrell R, Escudero-Vilaplana V, Romero-Jimenez R, Iglesias-Peinado \nI, Herranz-Alonso A, Sanjurjo-Saez M. Oral antineoplastic agent interactions \nwith medicinal plants and food: an issue to take into account. J Clin Oncol. \n2016;142(11):2319-30.\n28. Astin JA, Reilly C, Perkins C, Child WL, Susan GKBCF. Breast cancer pa -\ntients\u2019 perspectives on and use of complementary and alternative medicine: \na study by the Susan G. Komen Breast Cancer Foundation. J Clin Oncol. \n20 06;4(4):157- 69.\n29. Bott J. An analysis of paper-based sources of information on complementary \ntherapies. Complement Ther Clin Pract. 2007;13(1):53-62.\n30. Klafke N, Eliott JA, Wittert GA, Olver IN. Prevalence and predictors of com -\nplementary and alternative medicine (CAM) use by men in Australian cancer \noutpatient services. Ann Oncol. 2012;23(6):1571-8.\n004_10805- Uso de medicina complementaria en pacientes oncologicos.indd   600 24/08/2017   20:16", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}